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The role of transcriptional factor FOXO1 in the mechanism of drug-resistance in ovarian cancer has not been elucidated. In ovarian
cancer cell lines, FOXO1 expression and its correlation with paclitaxel treatment was investigated by cytotoxic assay and silencing
experiment. Clinical ovarian cancer samples were also examined for FOXO1 expression by immunohistochemistry. FOXO1
expression was distinctively upregulated in paclitaxel-resistant cell line, and enhanced by exposure to paclitaxel. FOXO1
overexpression was frequently observed in tissue samples from chemoresistant patients compared to chemosensitive patients.
FOXO1 silencing in paclitaxel-resistant cell line decreased its resistance. Modification of oxidative stress by co-treatment with
pharmacologic modulators of reactive oxygen species attenuated cytotoxicity of paclitaxel. Downstream targets of FOXO1 involving
oxidative stress were also attenuated in silencing experiment, suggesting its involvement in altered sensitivity to paclitaxel. These
results indicate that FOXO1 links to cytotoxic stress induced by paclitaxel and contributes to the drug-resistance in ovarian cancers.
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Paclitaxel is one of the most active cancer chemotherapeutic agents
known. It is effective against a variety of human tumours,
including ovarian carcinomas (Rowinsky and Donehower, 1995;
McGuire et al, 1996; Wiseman and Spencer, 1998). The efficacy of
paclitaxel is limited by intrinsic or acquired drug resistance in a
population of surviving malignant cells. One molecular mecha-
nisms for acquired tumour cell resistance to paclitaxel is explained
by overexpression of the drug efflux pump MDR-1; however, the
role of this is still undetermined.
The mammalian FOXO family of Forkhead transcription factors,
consisting of FOXO1, FOXO3a, and FOXO4, is a direct downstream
target of the PI3K/Akt pathway (Brunet et al, 1999; Kops et al,
1999). Post-translational modification of FOXO proteins is an
important mechanism that regulates the ability of different
transcription factors to activate distinct gene sets, involved in cell
cycle inhibition (Dijkers et al, 2000), apoptosis (Sunters et al,
2003), defense against oxidative stress and DNA repair (Kops et al,
2002; Nemoto et al, 2004). Since FOXO proteins were reported to
be critical mediators of apoptosis in cytotoxicity inducing drugs in
many cells (Sunters et al, 2003; Kajihara et al, 2006; Goto et al,
2008), we postulated that FOXO expression or transcriptional
activity could be important event in the drug sensitivity in cancer
cells. In the present study, we examined the consequence of
FOXO1 expression correlating with paclitaxel cytotoxicity and
sensitivity in ovarian cancer cell lines using parent cells and
paclitaxel-resistant derivative cells, and confirmed its expression
in clinical samples from chemosensitive and resistant patients.
Furthermore, we explored the possible underlying mechanism in
involvement of FOXO1 with paclitaxel resistance.
MATERIALS AND METHODS
Cell lines, culture conditions and treatment
KF28 is a single-cell clone of the human ovarian carcinoma cell line
KF. KFr13 is a cisplatin-resistant subline derived from KF28 cells
as described previously (Kikuchi et al, 1986), and KFr13Tx is a
paclitaxel-resistant subline derived from KFr13 cells (Yamamoto
et al, 2000a). These cell lines were grown as monolayer cultures in
RPMI-1640 (Immuno-Biological Laboratories Co. Ltd, Gunma,
Japan) medium supplemented with 10% fetal bovine serum
(Invitrogen Japan KK, Tokyo, Japan), 2mM glutamine, 100U
penicillin per ml, and 100mg streptomycin per ml (Invitrogen
Japan KK) in a humidified atmosphere of 5% CO2 at 371C, and
routinely tested for mycoplasma infection. Paclitaxel was obtained
from Bristol Meier’s Squib Oncology (Tokyo, Japan) and dissolved
in dimethylsulphoxide.
Cell proliferation and cytotoxicity assay
Ovarian cancer cells were seeded onto 96-well plates, at
approximately 2 10
3 or 10 10
3cellscm
 2 for proliferation or
cytotoxicity assays, respectively, and allowed to attach overnight.
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sCell viability was determined by MTS assay using the CellTiter 96
aqueous one solution cell proliferation assay (Promega KK Japan,
Tokyo, Japan) according to the manufacturer’s instructions. To
study the effects of paclitaxel on cell proliferation, cells were
treated with various doses of paclitaxel for 24h. After completion
of the treatment, the percentage absorbance was calculated against
untreated cells. For growth curve analysis and Trypan blue
exclusion test, ovarian cancer cells were plated in 24-well plates
(2 10
3 or 10 10
3cellscm
 2). At the indicated time points, cells
were trypsinised to detach from the plates and stained with Trypan
blue (Doujin, Kumamoto, Japan), and cell number was counted
under a microscopy using a haemocytometer. Each experiment
was performed in quadruplicate. Flow cytometry analysis was used
to quantify apoptosis in ovarian cancer cells by evaluating the sub-
G1 fraction (o2 N) after propidium iodide (PI) staining of ethanol-
fixed cells.
Western blotting analysis
Protein concentrations were determined by Bradford assay (Bio-
Rad Laboratories, Hercules, CA, USA) and equal amounts of whole
cell extracts or nuclear and cytoplasmic protein fractions were
separated on a 10% SDS–polyacrylamide gel before electrotransfer
onto a polyvinylidene diflouride membrane (Hybond P, GE
Healthcare UK Ltd, England, UK). Nonspecific binding sites were
blocked by overnight incubation with 5% dried skimmed milk in
Tris-buffered saline (130mM NaCl, 20mM Tris, pH 7.6). Primary
antibodies to FOXO1, phospho-FOXO1 (Ser256), Akt, phospho-
Akt (Ser473) (Cell Signaling Technology, Boston, MA, USA),
FOXO3a (Upstate, Temecula, CA, USA), FOXO4, GADD45a,
MnSOD, catalase, p27
Kip1, Lamin B1 (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA), and PARP cleavage site (214/215)
(Biosource, Carmavillo, CA, USA) were used at 1:1000 whereas the
antibody to b-actin (Abcam, Cambridge, UK) was diluted
1:100000. Primary antibodies were detected using horseradish
peroxidase linked anti-mouse, anti-goat or anti-rabbit conjugates as
appropriate (Dako Cytomation, Kyoto, Japan), and visualised using
the ECL detection system (GE Healthcare UK Ltd, England, UK).
Real-time quantitative–PCR
Total RNA was extracted from ovarian cancer cell lines by a ready-
to-use reagent (TRIZOL, Invitrogen Japan KK) according to the
manufacturer’s instructions and reverse transcribed using the
Superscript III reverse transcriptase (Invitrogen Japan KK), and
resulting first-strand cDNA was used as template in the real-time
quantitative–PCR (RTQ–PCR) analysis. The following gene-
specific primer pairs were used: L19-sense (50-GCGGAAGGGTACA
GCCAAT-30) and L19-antisense (50-GCAGCCGGCGCAAA-30);
FOXO1-sense (50-TGGACATGCTCAGCAGACATC-30) and FOXO1-
antisense (50-TTGGGTCAGGCGGTTCA-30). L19, a non-regulated
ribosomal housekeeping gene, served as an internal control and
was used to normalise for differences in input RNA. Detection of
the transcripts was performed with Power SYBR Green (Applied
Biosystems, Foster City, CA, USA) and an ABI PRISM 7700
sequence detection system according to the manufacturer’s
recommended protocol (Applied Biosystems). All measurements
were performed in triplicate.
Patient selection for immunohistochemical staining
Of patients with primary epithelial ovarian cancer treated at the
National Defense Medical College Hospital (Saitama, Japan), the
following patients were selected: (a) patients who received no
chemotherapy before any surgical therapy; (b) patients who
harboured measurable residual tumours after initial debulking
surgery; (c) patients who were treated with six courses of adjuvant
chemotherapy using paclitaxel (180mgm
 2) and carboplatin
(AUC¼5) chemotherapy after the initial surgery and (d) patients
who agreed to participate in the current study with written
informed consent. The patients were divided into the following
four groups according to their response to chemotherapy
measured with CT or MRI: (a) CR (complete response) group;
(b) PR (partial response) group; (c) SD (stable disease) group and
(d) PD (progressive disease) group. Responders were defined as
patients with CR or PR, and non-responders were defined as those
with SD and PD. A total of 13 responders and 10 non-responders
were included in the study.
Immunohistochemistry
After reviewing the haematoxylin-stained sections, a paraffin block
of the most representative sections were selected and cut into a
4-mm thickness. All of the sections were deparaffinised and
rehydrated with xylene and a graded alcohol series. To inactivate
endogenous peroxidase activity, sections were immersed in
methanol containing 0.3% hydrogen peroxide for 30min at room
temperature, then incubated in 2.0% blocking serum for the
reduction of nonspecific binding. The sections were incubated with
primary antibodies against FOXO1 (1:50 dilution; Cell Signaling
Technology, Boston, MA, USA) and MnSOD (1:50 dilution; Santa
Cruz Biotechnology Inc.) in humid chamber for 60min at room
temperature, followed by washing with PBS. For the visualisation
of FOXO1 and MnSOD, the EnVision
þt system (Dako Cytoma-
tion) was applied to the sections for 2h at room temperature, and
diaminobenzidine hydrochloride was used. These sections were
counterstained with Meyer’s haematoxylin. Cytoplasmic staining
was considered as positive expression. The proportion of positive-
stained cells was counted in more than 10 high power fields by two
investigators who were blinded to the data of patient character-
istics. Immunostaining for the specimen was classified as positive
when 410% of cells were positive.
Transient transfection
For silencing experiments, KFr13Tx cells cultured in six-well plates
were transfected with 50nM of FOXO1 siGENOME SMARTpool or
non-targeting siRNA pool (Dharmacon, Lafayette, CO, USA) using
Lipofectamine 2000 (Invitrogen Japan KK) according to the
manufacturer’s specifications. FOXO1 knockdown was confirmed
by western blot analysis in all the experiments.
Intracellular reactive oxygen species measurement
Levels of intracellular H2O2 were assessed spectrofluorimetrically
using 5-(and-6)-carboxy-20,70-dichlorodihydrofluorescein diace-
tate (carboxy-H2DCFDA, Invitrogen Japan KK) according to the
manufacturer’s instructions. Briefly, cells were seeded and attached
overnight on 96-well plates (2 10
4cellscm
 2) and were washed
with PBS and initially incubated with 10mM carboxy-H2DCFDA in
PBS for 30min, then changed to paclitaxel or H2O2 at the indicated
concentrations with carboxy-H2DCFDA in PBS concomitantly.
After 4h incubation, cells were washed with PBS and fluorescence
intensity was measured by spectrofluorometry. Excitation and
emission wavelengths used were 485 and 525nm, respectively. The
relative H2O2 production induced by paclitaxel or H2O2 was
expressed as the ratio between fluorescence intensity in cells
treated with paclitaxel or H2O2 and with PBS alone.
Statistical analysis
All values are presented as mean±s.d. Statistical significance
between two groups was determined by use of a two-tailed t-test
and values of Po0.05 were considered significant.
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sRESULTS
Cellular characterisation of ovarian cancer cell lines
To examine the role of FOXO transcriptional factor in ovarian
cancer cells, cellular characteristics, such as proliferation ability
and drug sensitivity, were first confirmed in three representative
ovarian cancer cell lines, parent cells KF28, cisplatin-resistant
derivative and paclitaxel-resistant derivative cells, KFr13 and
KFr13Tx. Cellular proliferation abilities in three cell lines were
comparable as determined by MTS assay (Figure 1A), which was
confirmed by growth curve analysis for KF28 and KFr13Tx
(Figure 1B). Drug sensitivity to paclitaxel was re-examined by
MTS assay after 24h exposure, which revealed considerable
acquired resistance only in KFr13Tx cells (Figure 1C). These
findings were also confirmed for KF28 and KFr13Tx cells treated
with 10nM paclitaxel for 24h by flow cytometry of PI-stained cells
(Figure 1D).
Differential expression of FOXO1 in ovarian cancer cell
lines
To clarify the role of FOXO transcriptional factor in ovarian
cancer, screening of FOXO protein expression was performed
using western blotting. Among these cells, KFr13Tx, paclitaxel-
resistant cell line, only showed marked FOXO1 expression in
protein level (Figure 2A). Comparing to FOXO1, FOXO3a and
FOXO4 did not show much difference among these cell lines. As
speculated, PI3K/Akt activity was considerably lower in KFr13Tx,
as reflected by the phosphorylated Akt levels. For further analysis,
the transcript levels were also examined by RTQ–PCR, which
revealed FOXO1 mRNA level was 15-fold highly expressed in
KFr13Tx cells compared to KF28 cells (Figure 2B). These results
prompted us to hypothesise that overexpression of FOXO1 in these
cell lines correlates especially with the mechanism of paclitaxel
resistance.
Immunohistochemical analysis of FOXO1 expression in
ovarian cancer samples from chemotherapy-responded
and non-responded patients
To investigate whether our in vitro data are relevant to clinical
practice, immunohistochemical reactivities of FOXO1 in ovarian
cancer samples, obtained at surgery before chemotherapy, with
different chemotherapeutic response to paclitaxel-based chemo-
therapy, were examined. Representative immunohistological stain-
ing of responder and non-responder are shown in Figure 2C.
FOXO1 overexpression with strong cytoplasmic staining was
observed in 5 of 10 non-responders (50%), whereas it was less
frequently detected in 2 of 13 responders (15%) (P¼0.073).
Immunoreactivity was not correlated with stage or histological
grade (data not shown).
Induction of FOXO1 by paclitaxel in ovarian cancer cell
lines
To investigate further the correlation of FOXO1 and paclitaxel,
FOXO1 expression was examined in KF28 and KFr13Tx cells
treated with paclitaxel at the increased concentrations for 24h.
Western blotting showed strong induced FOXO1 expression in
KFr13Tx cells by paclitaxel treatment, whereas its induction was
very weak in KF28 cells (Figure 3A). Conversely, cleaved PARP
expression as apoptosis marker was distinctively induced in KF28
cells, whereas its expression was almost undetectable in KFr13Tx
cells even at 100nM concentration, supporting the previous results
(Figure 1C and D). Again, RTQ–PCR was performed to examine
transcript levels of FOXO1 in both cells treated with 10nM
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Figure 1 Cellular characterisation of ovarian cancer cell lines. (A) KF28, KFr13 and KFr13Tx cells were seeded in 96-well plates and the relative increase in
cell viability was monitored by MTS assay at the indicated time points. (B) KF28 and KFr13Tx cells were plated in 24-well plates for growth curve analysis at
the indicated time points. Each experiment was performed in quadruplicate. (C) KF28, KFr13 and KFr13Tx were incubated with the indicated concentrations
of paclitaxel and cell viability was determined by MTS assay 24h later. (D) KF28 and KFr13Tx cells treated with 10nM paclitaxel were harvested at the
indicated time points and analysed by flow cytometry to determine the apoptotic cell fractions. The results show mean±s.d. of triplicate measurements and
**Po0.001.
Induction of FOXO1 by paclitaxel in ovarian cancers
T Goto et al
1070
British Journal of Cancer (2008) 98(6), 1068–1075 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
spaclitaxel at the indicated time points. FOXO1 mRNA expression
was induced in both cells, which were peaked after 24h, especially
marked in KFr13Tx cells (Figure 3B). For further analysis,
translocation of FOXO1 was also investigated using protein
fraction by western blotting. Nuclear translocation of FOXO1
was clearly observed in both cells, which were again peaked after
FOXO1
F
O
X
O
1
/
L
1
9
 
m
R
N
A
FOXO3a
FOXO4
Akt
pAkt
-Actin
K
F
r
1
3
K
F
r
1
3
T
x
K
F
2
8
KFr13Tx
KF28
0.8
0.6
0.4
0.2
0
**
Responder
Responder
FOXO1 expression
Chemotherapeutic response
Nonresponder
Nonresponder
Cases with overexpression
2/13 (15%) 5/10 (50%) 0.073
P-value
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of FOXO1, FOXO3a, FOXO4, total and phosphorylated Akt (pAkt) expression in KF28, KFr13 and KFr13Tx cells by western blot analysis. b-Actin served as
a loading control. (B) RTQ–PCR analysis demonstrated significant higher FOXO1 mRNA levels in KFr13Tx cells when compared to KF28 cells. The results
show mean±s.d. of triplicate measurements and **Po0.001. (C) The representative immunohistological staining of FOXO1 of a chemotherapy-responder
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Figure 3 Induction of FOXO1 by paclitaxel in ovarian cancer cell lines. (A) KF28 and KFr13Tx cells were incubated with the indicated concentrations of
paclitaxel for 24h and whole cell lysates were probed for FOXO1 and cleaved PARP expression by western blot analysis. b-Actin served as a loading
control. (B) KF28 and KFr13Tx cells treated with 10nM paclitaxel were harvested at the indicated time points, analysed by RTQ–PCR for FOXO1 mRNA
level. The results show mean±s.d. of triplicate measurements. (C) KF28 and KFr13Tx cells treated with 10nM paclitaxel were harvested at the indicated
time points and the whole cell lysates were probed for FOXO1 and phospho-FOXO1 expression, and cytosolic and nuclear protein fractions were also
probed for FOXO1 expression. b-Actin and Lamin B1 served as a loading control.
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s24h treatment (Figure 3C). The nuclear decrease after 48h
correlates with increase in phosphorylated (Ser256) FOXO1 levels
in cytosol. Notably, FOXO1 expression in the cytoplasmic fraction
was increased in KFr13Tx cells compared to KF28 cells, whereas
nuclear FOXO1 levels were comparable in both cells, which were
compatible with the previous results (Figure 2C).
FOXO1 attenuates sensitivity to paclitaxel-induced cell
death in paclitaxel-resistant cell lines
To clarify the role of FOXO1 in ovarian cancer cells, gene-silencing
experiment was performed in KFr13Tx cells. After transfection
with either non-targeting siRNA or FOXO1 siRNA, cellular
proliferation was monitored by MTS assay at the indicated time
points. FOXO1 siRNA slightly promoted cellular proliferation,
whose effect was not quite remarkable (Figure 4A). The same
silencing experiment was carried out before paclitaxel treatment at
the indicated concentrations for 24h. FOXO1 siRNA considerably
increased the sensitivity to paclitaxel as determined by MTS assay
(Figure 4B). These findings were again confirmed by FACS analysis
using PI staining for 24h treatment at 10nM paclitaxel (Figure 4C).
FOXO1 silencing followed by paclitaxel treatment in KFr13Tx cells
was again performed and putative FOXO target genes involving
with cell cycle inhibition (p27
Kip1), defence against oxidative stress
(MnSOD, catalase), and DNA repair (GADD45a) were examined by
western blotting. Transfection with FOXO1 siRNA decreased
expression levels of these target genes, especially in p27
Kip1 and
MnSOD, regardless of paclitaxel treatment (Figure 4D). Notably,
cleaved PARP was detectable by paclitaxel treatment only in
FOXO1 silencing cells, supporting the previous results (Figure 4B
and C).
Attenuation of oxidative stress by paclitaxel and FOXO1 in
ovarian cancer cell lines
To investigate the possible underlying mechanism that FOXO1
attenuates paclitaxel sensitivity in ovarian cancer cells, intracel-
lular reactive oxygen species (ROS) induced by paclitaxel was
measured in KF28 cells and KFr13Tx cells. As assessed by C-
H2DCFDA fluorescence, intracellular H2O2 levels were increased in
KF28 cells when exposed for 4h to increasing concentrations of
paclitaxel or H2O2 as indicated, whereas those changes were not
marked in KFr13Tx cells exposed with paclitaxel (Figure 5A).
To study further the role of ROS accumulation in paclitaxel
cytotoxicity, the effects of co-incubation of 10nM paclitaxel or
500mM H2O2 for 24h with antioxidant, 400mM N-acetylcysteine
(NAC), H2O2 scavenger, or 1mM NaN3, inhibitor of catalase, were
investigated in both cells by Trypan blue exclusion test. Co-
treatment with NAC or NaN3 in KF28 cells significantly decreased
or increased paclitaxel or H2O2 induced cell death, whereas co-
treatment with NaN3 in KFr13Tx cells also increased paclitaxel or
H2O2 induced cell death (Figure 5B). On the basis of these results,
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Figure 4 FOXO1 attenuates proliferation and sensitivity to paclitaxel-induced cell death in paclitaxel-resistant cell lines. (A) KFr13Tx cells seeded and
incubated in 96-well plates for 24h were transfected with either non-targeting (NT) siRNA or FOXO1 siRNA for 48h and cell viability was determined by
MTS assay at the indicated time points. (B) Loss of cell viability was determined by MTS assay in KFr13Tx cells first transfected with non-targeting (NT)
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results show mean±s.d. of triplicate measurements and **Po0.001. (D) Whole cell protein lysates of KFr13Tx cells transfected with non-targeting (NT)
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cytotoxicity through oxidative stress was studied again by ROS
measurement in KFr13Tx cells using silencing experiment. As
shown in Figure 5C, intracellular H2O2 levels were increased in
KFr13Tx cells transfected with FOXO1 siRNA compared to those
with NTsiRNA when exposed for 4h to increasing concentrations
of paclitaxel as indicated.
MnSOD expression in paclitaxel-sensitive and -resistant
ovarian cancer cell lines and ovarian cancer samples
To determine further the relevance of FOXO1 target genes in
ovarian cancer cells, we also compared the levels of p27
Kip1,
MnSOD, catalase and GADD45a expression in KF28, KFr13 and
KFr13Tx cells by western blotting. As shown in Figure 6A, p27
Kip1
and MnSOD were strongly expressed especially in paclitaxel-
resistant cell line, whereas GADD45a expression was also
comparably observed in KFr13 cells and catalase expressions were
almost the same among these three cell lines. Together with the
previous results, we speculated that the FOXO1 attenuates
paclitaxel sensitivity through control of oxidative stress by
regulation of MnSOD. Finally, again to investigate whether our
in vitro data is relevant to clinical practice, immunohistochemical
reactivities of MnSOD in the same ovarian cancer samples were
examined. Representative immunohistological staining of respon-
der and non-responder are shown in Figure 6B. MnSOD over-
expression with strong cytoplasmic staining was observed in 8 of
10 non-responders (80%), whereas it was less frequently detected
in 5 of 13 responders (38%) (P¼0.046). Furthermore, the cases
with overexpression of FOXO1 also showed MnSOD overexpres-
sion in non-responder patients.
DISCUSSION
Although most ovarian cancers are responsive to paclitaxel-based
chemotherapy, the emergence of drug-resistant cancer clones can
lead to treatment failure and disease relapse. There have been
several reports regarding overexpression of genes related to
paclitaxel resistance. MDR-1 overexpression in ovarian cancer cell
lines with paclitaxel resistance had been reported (Masanek et al,
1997; Duan et al, 1999). Similarly, we had also confirmed MDR-1
overexpression in paclitaxel-resistant derivative ovarian cancer cell
line, KFr13TX cells (Yamamoto et al, 2000b; Goto et al, 2006). The
molecular mechanism of MDR-1 is still uncertain. Some studies
showed MDR-1 as a predictive marker of poor chemotherapeutic
response (Yokoyama et al, 1999; Penson et al, 2004), but others did
not show (Baird and Kaye, 2003; Vasey, 2003; Mozzetti et al, 2005).
In the present study, paclitaxel-resistant derivative cells showed
increased expression of FOXO1, compared to parent cells and
cisplatin-resistant derivative cells. Notably, cytoplasmic FOXO1,
which is likely to be inactive and should have no affect on
expression of target genes in stress response, was strongly
expressed in resistant cells both in cancer cell lines and clinical
samples. In contrast, induction and nuclear FOXO1 was markedly
induced by 24h exposure of paclitaxel in both sensitive and
resistant cells. It is possible that acute exposure to paclitaxel leads
to FOXO1-dependent activation of a proapoptotic gene pro-
gramme, and that prolonged or chronic exposure promotes
selection of cells with another transcriptionally activated gene
settings by FOXO1, which are involved in cellular survival and
drug resistance. For instance, despite of the several reports
showing reduction in Akt phosphorylation in response to
paclitaxel, phosphorylation and nuclear exclusion of FOXO1 was
clearly observed after 48h in our experiments, especially stronger
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sin resistant cells. Since FOXO1 has recently been shown to enhance
Akt phosphorylation in hepatocytes by repressing the expression
of tribble 3 (Trb3), a pseudokinase capable of binding Akt and
inhibiting its phosphorylation (Matsumoto et al, 2006), it seems to
be interesting to investigate whether feedback to PI3K/AKT
pathway by FOXO1 could contribute to the survival advantage
and development of drug resistance. Although drug resistance in
cancer should be multifactorial, it is well recognised that a slower
growth rate represents one component of drug resistance. In our
results, FOXO1 silencing decreased expression level of p27
Kip1,
which is one FOXO1 target gene involving cell cycle inhibition
(Dijkers et al, 2000). However, cellular proliferation was not
actually attenuated in these cells, which suggests more critical
event other than cell growth retardation is involved in these
settings.
ROS are thought to play multiple roles including tumour
initiation, progression and maintenance, and ROS production is
highly increased in cancer cells (Szatrowski and Nathan, 1991;
Burdon, 1995). ROS levels fluctuate in response to intracellular as
well as extracellular signals and, in turn, stimulate specific
signalling cascades, such as MAPKs, that regulate cell growth
and cell death (Benhar et al, 2001; Davis et al, 2001; Tobiume et al,
2001). ROS levels are increased in cells exposed to various stress
agents, including paclitaxel and other anticancer drugs (Varbiro
et al, 2001; Ramanathan et al, 2005). Agents that decrease ROS can
suppress taxol-induced cytotoxicity, whereas increase of ROS
levels by inhibition of SOD or glutamylcysteine synthase can
enhance taxol-induced cytotoxicity in cancer cell lines (Rama-
nathan et al, 2005). The cellular responses to paclitaxel involve
activation of MAPK pathways (Bacus et al, 2001). Higher ROS
levels and SAPK (stress-activated protein kinases) JNK activity
were measured in tumour cells that were sensitive to anticancer
agents than in those that were drug-resistant, suggesting that ROS-
mediated JNK and p38 activation played a key role in the
sensitisation to stress signals and to anticancer drugs (Benhar et al,
2001; Davis et al, 2001). Thus, control of endogenous ROS level
and the regulation of MAPK pathway may involve in proliferation
and sensitivity to stress stimuli including anticancer drugs in
cancer cells. In the present study, the increase of intracellular H2O2
levels in ovarian cancer cells were observed by adding extracellular
H2O2 as well as paclitaxel. In addition, modifying intracellular ROS
level by co-incubation with NAC or catalase inhibitor showed
significant decrease or increase in cytotoxicity of H2O2 as well as
paclitaxel. Moreover, FOXO1 silencing attenuated intracellular
H2O2 levels, and also decreased expression of its putative target
gene, MnSOD and Gadd45a, simultaneously showing increased
paclitaxel-induced cytotoxicity, which collectively suggest one of
possible explanation in transcriptional role of FOXO1 as redox
mechanism to cytotoxic stimuli such as paclitaxel in these cells.
We also demonstrated in clinical samples that FOXO1 over-
expression was correlated with paclitaxel resistance, although the
number of samples was small and further analysis will be required
to confirm these findings. Among the FOXO1 target genes we
examined, MnSOD was strongly expressed especially in paclitaxel-
resistant cell line, which prompted us to speculate that FOXO1
might attenuate paclitaxel sensitivity through control of oxidative
stress by regulation of MnSOD, then confirmed its overexpression
in the same samples showing FOXO1 overexpression from
chemoresistant patients. There are far more mechanisms to
elucidate although, together with our in vitro data, FOXO1 might
be the candidate to predict the chemotherapeutic response and it
could be a molecular target for the treatment of drug-resistant
ovarian cancers.
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